Pharma Mar has filed a patent for combination therapies to treat solid tumors. The therapies involve administering lurbinectedin along with an immune checkpoint inhibitor, such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies. The patent claims that this combination therapy effectively treats solid tumors. GlobalData’s report on Pharma Mar gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Pharma Mar, Cancer treatment biomarkers was a key innovation area identified from patents. Pharma Mar's grant share as of September 2023 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Combination therapy for treating solid tumors using lurbinectedin and immune checkpoint inhibitor
A recently filed patent (Publication Number: US20230310426A1) describes a method for treating solid tumors using a combination therapy of lurbinectedin and an immune checkpoint inhibitor. The method involves administering the combination therapy to a patient in need of treatment.
The immune checkpoint inhibitor used in the therapy is an immunoglobulin molecule, preferably an antibody, that targets immune checkpoint molecules such as CTLA-4, PD-1, and PD-L1. The therapy may include multiple inhibitors targeting multiple immune checkpoint molecules, specifically CTLA-4 and PD-1. Monoclonal antibodies that specifically bind to CTLA-4, PD-1, or PD-L1 can be used, including pembrolizumab, nivolumab, ipilimumab, avelumab, atezolizumab, durvalumab, cemiplimab (REGN2810), camrelizumab (SHR1210), envafolimab (KN035), sintilimab (1131308), spartalizumab (PDR001), tislelizumab (BGB-A317), prolgolimab (BCD-100), toripalimab (JS001), dostarlimab (TSR-042, WBP-285), and tremelimumab (ticilimumab, CP-675,206).
The method allows for the concurrent, separate, or sequential administration of lurbinectedin and the immune checkpoint inhibitor. In one embodiment, lurbinectedin is administered initially, followed by the immune checkpoint inhibitor. Multiple administrations of either lurbinectedin, the immune checkpoint inhibitor, or both, may be given.
The solid tumors that can be treated using this method include prostate cancer, breast cancer, lung cancer, colorectal cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, esophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, lymphomas, ovarian cancer, pancreatic cancer, and sarcomas. Specifically, lung cancer, melanoma, and breast cancer are mentioned as examples.
The method may also involve determining whether the tumor expresses PD-L1 prior to beginning treatment. The treatment can result in various outcomes, including a reduction in tumor size, delay in tumor growth, prolongation of the patient's life, delay in disease progression, or remission.
Additionally, the patent describes the use of lurbinectedin, the immune checkpoint inhibitor, or the combination of both in the manufacture of a medicament for the treatment of solid tumors. It also mentions the inclusion of lurbinectedin and the immune checkpoint inhibitor in a pharmaceutical package.
In summary, the patent claims a method for treating solid tumors using a combination therapy of lurbinectedin and an immune checkpoint inhibitor. The therapy can be administered concurrently, separately, or sequentially, and may result in various positive outcomes for the patient. The patent also covers the use of lurbinectedin, the immune checkpoint inhibitor, or the combination of both in the manufacture of a medicament for the treatment of solid tumors.
To know more about GlobalData’s detailed insights on Pharma Mar, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
